-
Product Insights
Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelomonocytic Leukemia (CMML) - Drugs In Development, 2023’, provides an overview of the Chronic Myelomonocytic Leukemia (CMML) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Primary Immune Deficiency (PID) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Drugs In Development, 2023’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Severe Combined Immune Deficiency (SCID) – Drugs In Development, 2023
Global Markets Direct’s, ‘Severe Combined Immune Deficiency (SCID) - Drugs In Development, 2023’, provides an overview of the Severe Combined Immune Deficiency (SCID) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Combined Immune Deficiency (SCID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Acquired Gene or Chromosome Alterations Pipeline Market Report Overview Acquired Gene or Chromosome Alterations are reagents employed for genetic testing to detect cancer-causing or related alterations. The Acquired Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Inborn Gene or Chromosome Alterations Pipeline Product Market Overview The Inborn Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories · The US · Europe · Canada · China · Australia Key...
-
Track & Monitor
Cell & gene therapy in pharma: cancer CAR-T receptors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s cancer CAR-T receptors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Company Profile
Hutchinson SA – Company Profile
Hutchinson SA (Hutchinson), a subsidiary of Total SA, is a provider of customized materials and integrated solutions. It produces and sells body sealing systems, vibration control systems, fluid management systems, precision control systems, materials and structures and belt drive systems. The company’s product portfolio comprises car body sealing systems, door closures, door slides, door seals, structural and bodywork parts, beams, bumper protectors, side skirts, front and rear spoilers, fenders, and side bodywork. It also offers embedded electronic equipment, belt drives,...
Add to Basket